Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...
5d
Pharmaceutical Technology on MSNSupernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive.
Reality TV star and business mogul Kim Kardashian is facing a lawsuit over allegations that she falsely identified a New York ...
Clint Hill, the U.S. Secret Service agent who leaped atop John Kennedy's limousine to shield the mortally wounded president and long wondered if he could have saved him by acting quicker, has died at ...
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results